Kura Oncology

140 articles with Kura Oncology

• Kura Oncology to Participate in Credit Suisse Healthcare Conference

  11/2/2021

  Kura Oncology, Inc. today announced its participation in the Credit Suisse 30th Annual Healthcare Conference.

• Kura Oncology to Report Third Quarter 2021 Financial Results

  10/28/2021

  Kura Oncology, Inc. today announced that it will report third quarter 2021 financial results after the close of U.S. financial markets on Thursday, November 4, 2021.

• Kura Oncology Appoints Teresa Bair as Chief Legal Officer

  10/18/2021

  Kura Oncology, Inc. today announced the appointment of Teresa Bair as Chief Legal Officer and Corporate Secretary.

• Kura Oncology to Participate in Two Upcoming September 2021 Investor Conferences

  9/7/2021

  Kura Oncology, Inc., a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in two upcoming virtual investor conferences.

• Kura Oncology Reports Second Quarter 2021 Financial Results

  8/5/2021

  Kura Oncology, Inc., a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, reported second quarter 2021 financial results and provided a corporate update.

• Kura Oncology to Participate in Wedbush PacGrow Healthcare Virtual Conference

  8/4/2021

  Kura Oncology, Inc., a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, announced its participation in the Wedbush PacGrow Healthcare Virtual Conference.

• Kura Oncology to Report Second Quarter 2021 Financial Results

  7/29/2021

  Kura Oncology, Inc., a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, announced that it will report second quarter 2021 financial results after the close of U.S. financial markets on Thursday, August 5, 2021.

• Kura Oncology Appoints Helen Collins, M.D. to Board of Directors

  7/29/2021

  Kura Oncology, Inc., a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, announced the appointment of industry veteran Helen Collins, M.D., to its board of directors.

• Kura Oncology Announces Clinical Collaboration to Evaluate Tipifarnib in Combination with Alpelisib in Head and Neck Squamous Cell Carcinoma

  7/6/2021

  Combination of tipifarnib and alpelisib shows robust activity in preclinical PDX models of HRAS and PIK3CA pathway dependent tumors.

• Kura Oncology Doses First Patient in Phase 1b Expansion Cohorts with Menin Inhibitor KO-539

  6/24/2021

  – Phase 1b expansion cohorts designed to enable refinement of recommended Phase 2 dose – – At least 12 patients to be enrolled in each of two Phase 1b expansion cohorts: a 200 mg dose cohort and a 600 mg dose cohort – – Each cohort to be genetically enriched with NPM1-mutant and KMT2A-rearranged relapsed/refractory AML patients.

• Kura Oncology to Participate in JMP Securities Life Sciences Conference

  6/10/2021

  Kura Oncology, Inc. today announced its participation in the JMP Securities Life Sciences Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to present in a virtual fireside chat at 3:00 p.m. ET / 12:00 p.m. PT on Thursday, June 17, 2021.

• Kura Oncology Appoints Carol Schafer to Board of Directors

  6/4/2021

  Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the appointment of Wall Street veteran Carol Schafer to its board of directors, effective June 3, 2021.

• Kura Oncology to Participate in Cowen Virtual Oncology Innovation Summit

  5/13/2021

  Kura Oncology, Inc., a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, announced its participation in the Cowen 2nd Annual Virtual Oncology Innovation Summit.

• Kura Oncology Reports First Quarter 2021 Financial Results

  5/6/2021

  Menin inhibitor KO-539 continues to demonstrate compelling clinical activity, favorable safety/tolerability and a wide therapeutic window

• Kura Oncology to Report First Quarter 2021 Financial Results

  4/29/2021

  Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report first quarter 2021 financial results after the close of U.S. financial markets on Thursday, May 6, 2021.

• Kura Oncology Announces Publication of Tipifarnib Phase 2 Data in Journal of Clinical Oncology

  3/22/2021

  Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the publication of results from its RUN-HN study, a Phase 2 open-label, single-arm trial of tipifarnib in patients with HRAS mutant head and neck squamous cell carcinoma (HNSCC) whose disease had progressed after prior therapy

• Kura Oncology Reports Fourth Quarter and Full Year 2020 Financial Results

  2/24/2021

  – Preliminary clinical data for menin inhibitor KO-539 highlighted by single-agent activity in relapsed/refractory AML, including patients with NPM1 mutations – – KO-539 continues to demonstrate a wide therapeutic window in dose escalation; protocol amendment to include genetically enriched Phase 1 expansion cohorts

• Kura Oncology Receives FDA Breakthrough Therapy Designation for Tipifarnib in Head and Neck Squamous Cell Carcinoma

  2/24/2021

  Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that its investigational drug, tipifarnib, has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with recurrent or metastatic HRAS mutant head and neck squamous cell carcinoma

• Kura Oncology to Participate in Four Upcoming Investor Conferences - Feb 18, 2021

  2/18/2021

  Kura Oncology, Inc., a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, announced that Troy Wilson, Ph.D., J.D., President and Chief Executive officer is scheduled to participate in four upcoming virtual investor conferences:

• Kura Oncology to Report Fourth Quarter and Full Year 2020 Financial Results

  2/17/2021

  Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2020 financial results before the open of U.S. financial markets on Wednesday, February 24, 2021. Kura’s management will host a webcast and conference call at 8:00 a.m. ET / 5:00 a.m. PT that day to discuss the financial r